TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HURA TuHURA Biosciences, Inc.

休市中 05-22 16:00:00 EDT

2.50

+0.16

+6.84%

盘后2.45

-0.05-1.87%

19:54 EDT

最高2.59	最低2.33	成交量64.27万
今开2.33	昨收2.34	日振幅10.90%
总市值1.59亿	流通市值9,594万	总股本6,358万
成交额160.75万	换手率1.67%	流通股本3,838万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.5,"timestamp":1779480000000,"preClose":2.34,"halted":0,"volume":642714,"hourTrading":{"tag":"盘后","latestPrice":2.4533,"preClose":2.5,"latestTime":"19:54 EDT","volume":4806,"amount":11989.4354,"timestamp":1779494052238,"change":-0.0467,"changeRate":-0.01868,"amplitude":0.01896},"delay":0,"changeRate":0.06837606837606844,"floatShares":38376300,"shares":63578528,"eps":-0.61,"marketStatus":"休市中","change":0.16,"latestTime":"05-22 16:00:00 EDT","open":2.33,"high":2.585,"low":2.33,"amount":1607546.7446328,"amplitude":0.108974,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.61,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.34,"preHourTrading":{"tag":"盘前","latestPrice":2.3089,"preClose":2.34,"latestTime":"09:05 EDT","volume":92,"amount":215.63238760000002,"timestamp":1779455119449,"change":-0.0311,"changeRate":-0.013291,"amplitude":0.059316},"postHourTrading":{"tag":"盘后","latestPrice":2.4533,"preClose":2.5,"latestTime":"19:54 EDT","volume":4806,"amount":11989.4354,"timestamp":1779494052238,"change":-0.0467,"changeRate":-0.01868,"amplitude":0.01896},"volumeRatio":0.9900068023080972},"requestUrl":"/m/hq/s/HURA","defaultTab":"news","newsList":[{"id":"1136789265","title":"TuHURA生物科学公司与H.C. Wainwright & Co.达成市场发售协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1136789265","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136789265?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:35","pubTimestamp":1775680540,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司已与H.C. Wainwright & Co.正式签署市场发售协议，相关细节已通过美国证券交易委员会文件公开披露。该协议标志着公司在资本市场的战略布局取得新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195605532","title":"TuHURA生物科学公布2025年第四季度及全年财务业绩并发布公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1195605532","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195605532?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:46","pubTimestamp":1775044009,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司近日披露了其2025财年第四季度及全年的财务数据，同时向市场同步了企业最新动态。此次公告涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的阶段性成果。通过这份全面报告，投资者可清晰把握该公司在报告期内的运营状况与发展轨迹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613246866","title":"Tuhura Biosciences, Inc.盘中异动 早盘快速上涨8.18%报1.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613246866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613246866?lang=zh_cn&edition=full","pubTime":"2026-02-20 22:31","pubTimestamp":1771597903,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日22时31分，Tuhura Biosciences, Inc.股票出现异动，股价大幅上涨8.18%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612925624","title":"Tuhura Biosciences, Inc.盘中异动 快速下跌5.26%报1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612925624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612925624?lang=zh_cn&edition=full","pubTime":"2026-02-17 23:30","pubTimestamp":1771342229,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日23时30分，Tuhura Biosciences, Inc.股票出现波动，股价大幅跳水5.26%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Polaryx Therapeutics, Inc.、Quoin Pharmaceuticals Ltd、Eyepoint, Inc.涨幅较大，Ernexa Therapeutics Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为75.47%、58.89%、50.22%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Polaryx Therapeutics, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为27.14%、26.97%、25.79%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159427520","title":"TuHURA提交TBS-2025治疗血液类癌症的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1159427520","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159427520?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:50","pubTimestamp":1771332610,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. 已正式向监管机构递交了其候选药物TBS-2025的研究性新药申请，该药物旨在针对血液相关癌症开展临床治疗研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186309065","title":"TuHURA生物科学公司计划于2026年第二季度启动针对NPM1突变型复发/难治性急性髓系白血病的二期研究，初步一期结果将于2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1186309065","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186309065?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:48","pubTimestamp":1771332495,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司近日披露其研发管线的最新进展。该公司计划于2026年第二季度正式启动针对NPM1突变型复发/难治性急性髓系白血病的二期临床研究。这项研究旨在评估其在研疗法对该特定患者群体的安全性与有效性。\n与此同时，该药物一期临床研究的初步数据预计将于2026年第三季度揭晓。这些早期结果将为后续临床开发提供重要依据，并有助于优化二期试验的设计方案。公司表示，将严格遵循监管要求推进研究进程，力求为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608977807","title":"Tuhura Biosciences, Inc.盘中异动 快速下挫5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608977807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608977807?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:33","pubTimestamp":1770129200,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时33分，Tuhura Biosciences, Inc.股票出现波动，股价快速跳水5.55%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。该公司的个性化癌症候选疫苗 IFx-2.0 旨在克服对检查点抑制剂的主要耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169978766","title":"TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169978766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169978766?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:45","pubTimestamp":1770036316,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布，其研发的候选药物IFX-2.0已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，适应症为IIb期至IV期皮肤黑色素瘤。\n孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面，有望在药物开发及后续商业化进程中享受一系列政策支持，包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。\n此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601937463","title":"Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601937463?lang=zh_cn&edition=full","pubTime":"2026-01-08 04:02","pubTimestamp":1767816142,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日04时02分，Tuhura Biosciences, Inc.股票出现异动，股价急速上涨6.74%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为3.15%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Erasca, Inc.涨幅较大，Cardio Diagnostics Holdings Inc.、Pmgc Holdings Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1093.70%、682.96%、351.70%，振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Erasca, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为202.13%、67.49%、50.85%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150512948","title":"Tuhura Biosciences发布Kintara的应急价值权（CVR），因Kintara的Rem-001达到了主要安全目标，实现合同里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150512948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150512948?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:50","pubTimestamp":1765803053,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences发布Kintara的应急价值权（CVR），因Kintara的Rem-001达到了主要安全目标，实现合同里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183862465","title":"Tuhura Biosciences展示数据显示，Delta阿片受体（Dor）作为克服对免疫检查点抑制剂获得性耐药的新靶点，亮相第57届ASH年会暨博览会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183862465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183862465?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:51","pubTimestamp":1765198302,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences展示数据显示，Delta阿片受体（Dor）作为克服对免疫检查点抑制剂获得性耐药的新靶点，亮相第57届ASH年会暨博览会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":0.0823},{"period":"1month","weight":-0.0672},{"period":"3month","weight":1.1739},{"period":"6month","weight":0.4368},{"period":"1year","weight":-0.1694},{"period":"ytd","weight":2.3038}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司，成立于2009年6月24日，名称为Berry Only，Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法，以降低风险，满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤（GBM）和REM-001治疗皮肤转移性乳腺癌（CMBC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.054973},{"month":2,"riseRate":0.2,"avgChangeRate":0.076571},{"month":3,"riseRate":0.4,"avgChangeRate":0.006899},{"month":4,"riseRate":0.4,"avgChangeRate":-0.002636},{"month":5,"riseRate":0.6,"avgChangeRate":1.089936},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.040545},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.01467},{"month":8,"riseRate":0.5,"avgChangeRate":-0.086193},{"month":9,"riseRate":0.3,"avgChangeRate":-0.103258},{"month":10,"riseRate":0.4,"avgChangeRate":-0.116072},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.220735}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}